

ABSTRACT OF THE DISCLOSURE

The invention relates to recombinant Arterivirus replicons. The invention provides the insight that an Arterivirus replicon having at least some of its original arteriviral nucleic acid encoding ORF-7 deleted, as provided herein, can still be capable of *in vivo* RNA replication, even when further comprising nucleic acid derived from at least one heterologous micro-organism, thereby also providing viable Arteriviruses with deletions proximal to the 3' end of the genome.